This is a working overview of peptide hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Chain strength == The most common measure of roller chain's strength is tensile strength. Tensile strength represents how much load a chain can withstand under a one-time load before breaking. Just as important as tensile strength is a chain's fatigue strength. The critical factors in a chain's fatigue strength is the quality of steel used to manufacture the chain, the heat treatment of the chain components, the quality of the pitch hole fabrication of the linkplates, and the type of shot plus the intensity of shot peen coverage on the linkplates. Other factors can include the thickness of the linkplates and the design (contour) of the linkplates. The rule of thumb for roller chain operating on a continuous drive is for the chain load to not exceed a mere 1/6 or 1/9 of the chain's tensile strength, depending on the type of master links used (press-fit vs. slip-fit). Roller chains operating on a continuous drive beyond these thresholds can and typically do fail prematurely via linkplate fatigue failure. The standard minimum ultimate strength of the ANSI 29.1 steel chain is 12,500 x (pitch, in inches)2. X-ring and O-Ring chains greatly decrease wear by means of internal lubricants, increasing chain life. The internal lubrication is inserted by means of a vacuum when riveting the chain together.
=== Nora Braverman === Nora Braverman (Mia and Ella Allan), the youngest of Adam and Kristina's three children, was born in late 2011. Her father Adam was negotiating a huge business deal at the time of her birth and was unable to get phone signal coverage; as a result, his brother, Crosby, helped Adam's wife deliver the child.
Sheila Sue Moriber Katz (February 1, 1943 – September 10, 2023) was an American pathologist and writer, dean of the Hahnemann University School of Medicine, and co-founder of the School of Public Health at Drexel. She is sometimes described as the first person to see the bacterium Legionella pneumophila, which causes Legionnaires' disease.
== Further reading == "Imaging Trace Metals in Biological Systems" pp 81–134 in "Metals, Microbes and Minerals: The Biogeochemical Side of Life" (2021) pp xiv + 341. Authors Yu, Jyao; Harankhedkar, Shefali; Nabatilan, Arielle; Fahrni, Christopher; Walter de Gruyter, Berlin. Editors Kroneck, Peter M.H. and Sosa Torres, Martha. DOI 10.1515/9783110589771-004
Sources: en.wikipedia.org
=== Reasons for splits and cracks during timber drying and their control === The chief difficulty experienced in the drying of timber is the tendency of its outer layers to dry out more rapidly than the interior ones. If these layers are allowed to dry much below the fibre saturation point while the interior is still saturated, stresses (called drying stresses) are set up because the shrinkage of the outer layers is restricted by the wet interior. Rupture in the wood tissues occurs, and consequently splits and cracks occur if these stresses across the grain exceed the strength across the grain (fibre to fibre bonding). The successful control of drying defects in a drying process consists in maintaining a balance between the rate of evaporation of moisture from the surface and the rate of outward movement of moisture from the interior of the wood. The way in which drying can be controlled will now be explained. One of the most successful ways of wood drying or seasoning would be kiln drying, where the wood is placed into a kiln compartment in stacks and dried by steaming, and releasing the steam slowly.
The liquid containing the analytes of interest (typically 10−6 - 10−4 M needed ) is dispersed by electrospray, into a fine aerosol. Because the ion formation involves extensive solvent evaporation (also termed desolvation), the typical solvents for electrospray ionization are prepared by mixing water with volatile organic compounds (e.g. methanol acetonitrile). To decrease the initial droplet size, compounds that increase the conductivity (e.g. acetic acid) are customarily added to the solution. These species also act to provide a source of protons to facilitate the ionization process. Large-flow electrosprays can benefit from nebulization of a heated inert gas such as nitrogen or carbon dioxide in addition to the high temperature of the ESI source. The aerosol is sampled into the first vacuum stage of a mass spectrometer through a capillary carrying a potential difference of approximately 3000 V, which can be heated to aid further solvent evaporation from the charged droplets. The solvent evaporates from a charged droplet until it becomes unstable upon reaching its Rayleigh limit. At this point, the droplet deforms as the electrostatic repulsion of like charges, in an ever-decreasing droplet size, becomes more powerful than the surface tension holding the droplet together. At this point the droplet undergoes Coulomb fission, whereby the original droplet 'explodes' creating many smaller, more stable droplets. The new droplets undergo desolvation and subsequently further Coulomb fissions.
=== Present day === Modern embalming is most often performed to ensure a better presentation of the deceased for viewing by friends and relatives. It is also used for medical research or training, transportation of deceased, especially across national borders, and in many instances for above ground burial in a vault or mausoleum. A successful viewing of the body is considered to be helpful in the grieving process. Embalming has the potential to prevent mourners from having to deal with the decomposition and eventual putrescence of the body. Despite a common misconception, embalming is not mandatory in the United States, although it is a general legal requirement for international repatriation of human remains to the U.S. (exceptions do occur). There are no universal international preservation requirements for repatriation of human remains, but requirements for embalming do exist for a variety of countries depending on locality and circumstance. Some international standards do exist however, such as the Strasbourg Agreement of the Council of Europe, agreed to by more than 20 States in Europe, which only requires embalming in cases where the individual died due to an infectious disease.
=== Polymerization and hydration === Monomeric CH2O is a gas and is rarely encountered in the laboratory. Aqueous formaldehyde, unlike some other small aldehydes (which need specific conditions to oligomerize through aldol condensation) oligomerizes spontaneously at a common state. The trimer 1,3,5-trioxane, (CH2O)3, is a typical oligomer. Many cyclic oligomers of other sizes have been isolated. Similarly, formaldehyde hydrates to give the geminal diol methanediol, which condenses further to form hydroxy-terminated oligomers HO(CH2O)nH. The polymer is called paraformaldehyde. The higher concentration of formaldehyde—the more equilibrium shifts towards polymerization. Diluting with water or increasing the solution temperature, as well as adding alcohols (such as methanol or ethanol) lowers that tendency. Gaseous formaldehyde polymerizes at active sites on vessel walls, but the mechanism of the reaction is unknown. Small amounts of hydrogen chloride, boron trifluoride, or stannic chloride present in gaseous formaldehyde provide the catalytic effect and make the polymerization rapid.
=== Cameos === Charlize Theron made a cameo appearance as Stormfront in the fictional film within the series Dawn of the Seven in the episode "Payback". Billy Zane portrayed Alastair Adana in another fictional film within the series Not Without My Dolphin. Jaz Sinclair appeared ahead of starring in the spinoff series Gen V in a photograph as Marie Moreau for the episode "The Only Man in the Sky". Seth Rogen portrayed himself as the SupePorn.com patron "SirCumsALot779" in the episode "The Last Time to Look on This World of Lies". Uncredited Patton Oswalt, Josh Gad, Ashton Kutcher, Mila Kunis, Elizabeth Banks, Kumail Nanjiani, Aisha Tyler, and Rose Byrne appeared as fictionalized versions of themselves parodying Gal Gadot's universally panned COVID-19 lockdown celebrity supergroup cover of "Imagine", in the order of their appearance respectively singing on YouTube for the opening scene of the episode "Herogasm".
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.